Hepatorenal syndrome represents one of the most serious complications that can develop in people living with advanced liver disease, bringing the urgent challenge of kidney failure to those already battling severe hepatic conditions. While the situation is critical and requires immediate medical attention, modern medicine offers several approaches aimed at supporting kidney function and potentially bridging patients toward the possibility of liver transplantation, which remains the definitive solution for this complex condition.

When the Liver and Kidneys Stop Working Together

The journey of managing hepatorenal syndrome begins with understanding what doctors are trying to achieve. The main goal of treatment is not simply to reverse kidney failure, but rather to stabilize the patient’s condition, slow down the progression of both liver and kidney dysfunction, and improve quality of life during a very difficult time. Treatment decisions depend heavily on how far the disease has progressed, which type of hepatorenal syndrome the person has developed, and whether the patient is healthy enough to be considered for liver transplantation.^[1]

Medical professionals follow treatment guidelines that have been established by major liver disease societies around the world. These guidelines recommend a combination of approaches, including medications already proven effective in clinical practice, supportive measures to maintain vital organ function, and when appropriate, consideration of cutting-edge therapies being tested in clinical research trials. The reality is that hepatorenal syndrome carries a very poor outlook without intervention, which makes every treatment decision critically important.^[2]

Understanding the two main forms of this condition helps explain why treatment approaches may differ. Type 1 hepatorenal syndrome, now often called HRS-AKI (hepatorenal syndrome with acute kidney injury), develops rapidly, sometimes over just days or weeks, and represents a medical emergency. Type 2 hepatorenal syndrome, now referred to as HRS-NAKI (non-acute kidney injury), progresses more slowly and is often accompanied by fluid buildup in the abdomen that doesn’t respond well to standard treatments. Each type requires its own strategy, though both ultimately point toward the need for liver transplantation if the patient is eligible.^[3]

Standard Medical Approaches Currently in Use

The foundation of treating hepatorenal syndrome rests on addressing factors that may have triggered the kidney failure while providing supportive care. One of the first steps doctors take is stopping medications that might be making kidney function worse. This includes diuretics, which are “water pills” that help remove excess fluid but can sometimes reduce blood flow to the kidneys. Similarly, medications called nonsteroidal anti-inflammatory drugs (NSAIDs) must be avoided because they can further compromise kidney function in this vulnerable state.^[7]

Volume expansion with albumin, a protein found naturally in blood, has become a cornerstone of treatment. Albumin is given through an intravenous line to help maintain blood pressure and improve blood flow to the kidneys. This isn’t just any fluid replacement—albumin appears to have special properties that help stabilize the circulatory system in people with severe liver disease. Doctors typically combine albumin with other medications that cause blood vessels to constrict, redirecting blood flow toward the kidneys.^[8]

The most widely used medication for hepatorenal syndrome is terlipressin, a drug that belongs to a class called vasopressin analogues. Terlipressin works by narrowing blood vessels in the digestive system, which in turn helps redirect blood toward the kidneys. When combined with albumin, terlipressin has shown the ability to improve kidney function in many patients. However, it’s important to note that terlipressin is not approved for use in all countries, including the United States, though it is available in Europe and other regions.^[9]

An alternative to terlipressin involves using a combination of two medications: octreotide and midodrine. Octreotide is a somatostatin analogue that helps reduce blood flow to the digestive organs, while midodrine stimulates receptors that cause blood vessels to narrow. Together with albumin, these medications attempt to achieve the same goal as terlipressin—improving blood flow to the kidneys. Some studies suggest this combination may be slightly less effective than terlipressin, but it provides an option when terlipressin isn’t available.^[9]

Another medication that has shown promise is norepinephrine, a naturally occurring hormone that powerfully constricts blood vessels. Research comparing norepinephrine to terlipressin suggests that norepinephrine may be just as beneficial, and it has the advantage of being more widely available in many healthcare settings. It must be given through a continuous intravenous infusion, which typically requires monitoring in an intensive care unit.^[8]

When medications alone aren’t enough, some patients may need renal replacement therapy, which is a form of dialysis. Dialysis mechanically removes waste products and excess fluid from the blood when the kidneys can no longer perform this function. In hepatorenal syndrome, dialysis is usually considered a temporary measure—a bridge to keep patients alive while waiting for liver transplantation. The type of dialysis most commonly used is called continuous veno-venous hemofiltration, which is gentler on the body than standard dialysis and better tolerated by people with unstable blood pressure.^[9]

Treating any underlying infections is also crucial. About one-third of patients with spontaneous bacterial peritonitis—a serious infection of the fluid in the abdomen—will develop hepatorenal syndrome. Prompt treatment with antibiotics, particularly cefotaxime or other third-generation cephalosporins, can sometimes prevent hepatorenal syndrome from developing or worsening. If fluid buildup in the abdomen becomes severe, a procedure called paracentesis may be performed to drain large volumes of fluid, always followed by albumin infusion to maintain blood volume.^[9]

Procedural Interventions and Surgical Options

For select patients, a procedure called transjugular intrahepatic portosystemic shunt, or TIPS, may be considered. This procedure involves creating a new pathway for blood flow within the liver, bypassing areas of scarring that are causing high pressure in the portal vein—the main blood vessel that supplies the liver. By reducing this pressure, TIPS can improve kidney function in some cases. The procedure is performed by specialized interventional radiologists who thread a catheter through veins to reach the liver and place a small metal tube that serves as the new pathway.^[14]

TIPS has shown particular benefit for patients with Type 2 hepatorenal syndrome who have persistent fluid buildup. Studies have documented improvements in laboratory markers of kidney function, including decreased creatinine levels and increased urine output, within weeks to months after TIPS placement. However, the procedure is not without risks. It can worsen hepatic encephalopathy—a condition where toxins build up in the brain, causing confusion and altered consciousness. Additionally, TIPS may precipitate liver failure in patients whose liver function is already severely compromised.^[14]

The decision to proceed with TIPS requires careful evaluation. Doctors must weigh the potential benefits against the risks, considering factors like the patient’s overall liver function, presence of encephalopathy, and candidacy for transplantation. In some transplant centers, TIPS is viewed as a bridge therapy—something that can stabilize a patient and improve their kidney function while they wait for a donor liver to become available.^[14]

Liver transplantation itself is the only definitive cure for hepatorenal syndrome. When a person receives a new, healthy liver, kidney function typically improves dramatically, often returning to normal within weeks to months. This remarkable recovery confirms that hepatorenal syndrome is indeed a functional problem rather than structural kidney damage. The kidneys themselves are usually healthy; they simply can’t function properly because of the effects of advanced liver disease on the body’s circulatory system.^[2]

However, access to liver transplantation is limited by the shortage of donor organs. Waiting times can be long, and many patients with hepatorenal syndrome deteriorate rapidly. This is why all the other treatments described—medications, dialysis, TIPS—are often referred to as bridge therapies. They’re meant to keep patients alive and as stable as possible until transplantation can occur. Patients who successfully receive medical treatment for hepatorenal syndrome before transplantation appear to have survival outcomes after transplant that are comparable to those who didn’t develop hepatorenal syndrome.^[9]

Emerging Therapies Being Investigated in Clinical Trials

Because current treatments for hepatorenal syndrome have significant limitations, researchers around the world are actively studying new approaches. Clinical trials represent hope for patients who don’t respond to standard therapies or who need more effective treatment options. These studies are being conducted at various stages, each designed to answer specific questions about safety, effectiveness, and optimal use of new treatments.^[5]

Understanding clinical trial phases helps clarify what researchers are trying to learn. Phase I trials focus primarily on safety, testing new treatments in small groups of people to determine appropriate doses and identify side effects. Phase II trials expand to larger groups and begin evaluating whether the treatment actually improves kidney function or other important outcomes. Phase III trials involve even larger numbers of patients and compare the new treatment directly against current standard treatments or placebo to definitively establish effectiveness. Participation in these trials may be available to eligible patients at specialized medical centers in various countries.^[5]

Novel vasoconstrictors with different mechanisms of action are under investigation. Some experimental drugs target specific receptors in blood vessels with the goal of more precisely controlling where blood flows in the body. The theoretical advantage would be better redirection of blood to the kidneys with fewer side effects on the heart and other organs. While specific drug names and trial results haven’t been widely published yet, research institutions in the United States, Europe, and other regions continue enrolling patients in these studies.^[5]

Artificial liver support systems represent another area of active investigation. These devices work somewhat like dialysis machines but are designed to temporarily take over some of the liver’s functions, not just the kidneys’. By removing toxins and inflammatory substances from the blood, these systems might help stabilize patients with hepatorenal syndrome. Several types of artificial liver support have been developed, including systems that use albumin dialysis or blood passing through liver cells grown outside the body. While still largely experimental, these approaches show promise for patients who aren’t responding to medications alone.^[8]

Research into the molecular mechanisms underlying hepatorenal syndrome has revealed several potential therapeutic targets. Scientists have identified that an imbalance between substances that widen blood vessels and those that narrow them plays a central role in the condition. This has led to investigation of medications that might help restore this balance. For example, drugs that affect the renin-angiotensin-aldosterone system—a hormone system that regulates blood pressure and fluid balance—are being studied, though results have been mixed so far.^[5]

Anti-inflammatory therapies are also being explored based on the understanding that inflammation contributes to hepatorenal syndrome. When the liver is severely damaged, inflammatory molecules circulate throughout the body and affect blood vessel function. Treatments that reduce this inflammation might help preserve kidney function. Some studies are examining medications that block specific inflammatory pathways, though this research is still in relatively early stages.^[5]

Improvements in prevention strategies represent another focus of research. Studies have shown that giving albumin to patients when they develop spontaneous bacterial peritonitis significantly reduces their risk of developing hepatorenal syndrome. Research is ongoing to determine if albumin or other preventive treatments might benefit patients with other triggering conditions, such as large-volume fluid removal from the abdomen or gastrointestinal bleeding. Understanding which patients are at highest risk for developing hepatorenal syndrome could allow for earlier, more targeted preventive interventions.^[9]

Most Common Treatment Methods

• Volume Expansion Therapy
  • Intravenous albumin infusion to maintain blood pressure and improve blood flow to kidneys
  • Fluid resuscitation with careful monitoring to avoid overload
  • Electrolyte balance management through intravenous solutions
• Vasoconstrictor Medications
  • Terlipressin combined with albumin as first-line treatment in regions where available
  • Octreotide plus midodrine with albumin as alternative combination therapy
  • Norepinephrine infusion for patients in intensive care settings
  • Treatment typically continues for several weeks with monitoring of kidney function
• Renal Replacement Therapy
  • Continuous veno-venous hemofiltration for gentle, ongoing dialysis support
  • Standard hemodialysis in some cases when continuous therapy unavailable
  • Used as bridge to liver transplantation rather than permanent solution
• Infection Management
  • Antibiotic treatment with third-generation cephalosporins for spontaneous bacterial peritonitis
  • Prophylactic antibiotics in some high-risk situations
  • Albumin administration alongside antibiotics to prevent hepatorenal syndrome development
• Procedural Interventions
  • Transjugular intrahepatic portosystemic shunt (TIPS) to reduce portal hypertension
  • Large-volume paracentesis with albumin replacement for severe ascites
  • Procedures performed by interventional radiology specialists
• Medication Adjustments
  • Discontinuation of diuretics that may worsen kidney function
  • Avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Careful review of all medications to eliminate nephrotoxic agents
• Liver Transplantation
  • Definitive curative treatment for hepatorenal syndrome
  • Kidney function typically recovers after successful liver transplant
  • All other treatments considered as bridge therapies to transplantation